GABA Plus Liraglutide Reverses Diabetes and Restores Pancreatic Islets in Wolfram Syndrome Rats

Five-month-old glucose-intolerant Wolfram syndrome rats and wild-type littermates received daily treatment with GABA (1 g/kg/day), liraglutide (0.4 mg/kg/day), or both for four months. Diabetes was monitored via intraperitoneal glucose tolerance tests with insulin and hormone measurements by ELISA. Post-treatment immunohistochemistry assessed islet morphology, cellular distribution, and beta-cell health markers.

Wolfram syndrome currently has no approved treatments, and patients face progressive diabetes, blindness, and neurodegeneration. Finding that a readily available combination — a GLP-1 drug already on the market plus GABA (a dietary supplement) — can reverse the diabetic phenotype and restore pancreatic tissue offers hope for a condition that has had virtually no therapeutic options.

This study sits at the intersection of rare disease research and GLP-1 peptide therapeutics. While GLP-1 agonists are primarily known for type 2 diabetes and obesity, their potential in rare genetic forms of diabetes like Wolfram syndrome could expand their clinical reach. The synergy with GABA — which alone was ineffective — demonstrates that combination approaches may unlock therapeutic benefits impossible with single agents, a principle applicable across peptide medicine.

This is a rat model study, and Wolfram syndrome in rats may not perfectly replicate the human disease. The sample sizes typical of rare disease animal models are small. Four months of treatment may not predict lifelong outcomes. GABA dosing at 1 g/kg/day is very high and may not be practical in humans. The mechanisms underlying the synergistic effect were not fully elucidated.